- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05816330
L9LS MAb in Malian Adults
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Adults in Mali
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A phase 2 trial evaluating the safety and tolerability of a one time subcutaneous (SC) administration of L9LS, as well its protective efficacy against naturally occurring Pf infection over a 6-month malaria season. The primary study hypotheses is that L9LS will be safe and protective against malaria infection. As a secondary objective, the efficacy of L9LS within three body weight strata among female participants will each be compared to placebo. Before study agent administration, all subjects will be given artemether lumefantrine to clear any preexisting Pf blood stage infection.
The study is a randomized, double-blind, placebo-controlled, sex-stratified (2:1 female to male ratio) and weight-stratified trial (N=288 total) with 2 treatment arms: L9LS 900 mg SC (n=216) and placebo (n=72) to assess safety and protective efficacy of L9LS compared to placebo.
Subjects will receive the study agent and be followed at study visits 1, 3, 7, 14, 21, and 28 days later, and once every 2 weeks thereafter through 24 weeks. Primary study assessments include physical examination and blood collection for identification of Pf infection and other research laboratory evaluations.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kassoum Kayentao, MD, MPH, PhD
- Phone Number: +223 7646 0173
- Email: kayentao@icermali.org
Study Contact Backup
- Name: Boubacar Traore, PharmD, PhD
- Phone Number: +223 2022 8109
- Email: bouba.traore@mrtcbko.org
Study Locations
-
-
Région De Koulikoro
-
Faladje, Région De Koulikoro, Mali
- Faladje MRTC Clinic
-
Kalifabougou, Région De Koulikoro, Mali
- Kalifabougou MRTC Clinic
-
Torodo, Région De Koulikoro, Mali
- Torodo MRTC Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females aged ≥18 and ≤49 years and weighing ≥ 45.0 and ≤ 90.0 kg.
- Males aged ≥18 and ≤55 years and weighing ≥ 50.0 and ≤ 100.0 kg.
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
- In good general health and without clinically significant medical history.
- Able to provide informed consent.
- Willing to have blood samples and data stored for future research.
- Resides in or near Kalifabougou, Faladje, or Torodo, Mali, and available for the duration of the study.
Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below.
- Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
- Nonchildbearing women will be required to report date of last menstrual period, history of surgical sterility (i.e., tubal ligation, hysterectomy) or premature ovarian insufficiency, and will have urine or serum pregnancy tests performed per protocol.
Exclusion Criteria:
- Pregnancy, as determined by a positive urine or serum beta-human choriogonadotropin (β hCG) test (if female).
- Currently breastfeeding.
- Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol.
- Study comprehension examination score of <80% correct or per investigator discretion.
- Hemoglobin, white blood cell, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
- Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
- Infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
- Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.)
- Clinically significant abnormal electrocardiogram (ECG; QTc >460 or other significant abnormal findings, including unexplained tachycardia or bradycardia).
- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
- Receipt of any investigational product within the past 30 days.
- Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. [Note: Past, current, or planned participation in observational studies is NOT exclusionary; participation in the placebo arm of the Mali adult CIS43LS MAb trial (ClinicalTrials.gov Identifier: NCT04329104) is NOT exclusionary.]
- Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
- History of a severe allergic reaction or anaphylaxis.
- Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
- Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia.
- Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
- Known immunodeficiency syndrome.
- Known asplenia or functional asplenia.
- Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of day 0.
- Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration.
- Receipt of immunoglobulins and/or blood products within the past 6 months.
- Previous receipt of an investigational malaria vaccine or monoclonal antibody in the last 5 years.
- Known allergies or contraindication against artemether lumefantrine.
- Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or render the subject unable to comply with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: 900 mg of L9LS SC
Participants will receive 900 mg of L9LS SC.
|
Administered one time via subcutaneous route.
|
Placebo Comparator: Arm 2: Placebo (normal saline) SC
Participants will receive placebo of Normal Saline for comparison.
|
Administered one time via subcutaneous route.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of local and systemic AEs occurring within 7 days after the administration of study agent.
Time Frame: Measured through Day 7
|
Measured through Day 7
|
|
Severity of local and systemic AEs occurring within 7 days after the administration of study agent.
Time Frame: Measured through Day 7
|
Measured through Day 7
|
|
Occurrence of Pf blood-stage infection
Time Frame: Measured through Week 24
|
Detected by microscopic examination of thick blood smear for 24 weeks after administration of study agent.
|
Measured through Week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pf blood-stage infection as detected by RT-PCR for 24 weeks after administration of study agent.
Time Frame: Measured through week 24
|
Measured through week 24
|
Measurement of L9LS in sera of recipients.
Time Frame: Measure through week 24
|
Measure through week 24
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kassoum Kayentao, MD, MPH, PhD, Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS)
- Principal Investigator: Peter Crompton, MD, MPH, National Institutes of Health (NIH)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/109/CE/USTTB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on L9LS (VRC-MALMAB0114-00-AB)
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); University of Washington; Harvard School... and other collaboratorsActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States, Puerto Rico, Zimbabwe, South Africa
-
National Institute of Allergy and Infectious Diseases...TerminatedHealthy Adult Immune ResponseUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedMonoclonal Antibody, Human | HIV Antibodies | Neutralizing Antibody | Prevention of HIV InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States, South Africa
-
National Institute of Allergy and Infectious Diseases...AIDS Clinical Trials GroupCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infection | Monoclonal Antibody, Human | HIV Antibodies | VRC01 Monoclonal Antibody | Neutralizing AntibodyUnited States
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting